Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Sacubitril/valsartan in chronic heart failure – early clinical experience from a tertiary centre

Danish Ali, Jacqui Hyland, Fiona Riley, Stephanie Kirkland, Sarah Al Bared, Parekh Rajen, Lisa Hinitt, Catherine Watson, Hayley Nicholson, Umar Fraz and Prithwish Banerjee
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.19-2-s21
Clin Med March 2019
Danish Ali
University Hospitals Coventry and Warwickshire NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqui Hyland
University Hospitals Coventry and Warwickshire NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiona Riley
University Hospitals Coventry and Warwickshire NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Kirkland
University Hospitals Coventry and Warwickshire NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Al Bared
University Hospitals Coventry and Warwickshire NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Parekh Rajen
University Hospitals Coventry and Warwickshire NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Hinitt
University Hospitals Coventry and Warwickshire NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Watson
University Hospitals Coventry and Warwickshire NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hayley Nicholson
University Hospitals Coventry and Warwickshire NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Umar Fraz
University Hospitals Coventry and Warwickshire NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prithwish Banerjee
University Hospitals Coventry and Warwickshire NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Aims

We report our clinical experience of sacubitril/valsartan (SV) use in heart failure (HF) patients at a large UK cardiac centre.

Methods

Heart failure with reduced ejection fraction (HFrEF) patients seen in the HF clinic and started on SV from April 2016 to July 2017 were retrospectively evaluated. Change in New York Heart Association (NYHA) class, estimated glomerular filtration rate (eGFR), up-titration to target dose and tolerability to SV were assessed. Six-month and 1-year outcomes of mortality and HF hospitalisations were evaluated. Patients were seen in the nurse-led, cardiologist-supervised, HF clinic at 4-weekly intervals until up-titration to maximum tolerated dose.

Results

A total of 140 patients were included (Table 1) and in 77 patients (55%) up-titration to the target dose was achieved (Table 2). An improvement of NYHA class was seen in 43 (31%) patients and left ventricular ejection fraction (LVEF) improved in 23 (66%) patients. 44 (31%) patients had symptomatic systolic blood pressure drop of >10 mmHg at follow up preventing target dose up-titration. Eight (6%) HF admissions and five (4%) in-hospital deaths occurred in 6 months. Of the total cohort of 140, 1-year outcome was observed in 68 patients with a mortality of 7% (n=5) and HF admission of 6% (n=4). Fifteen (10%) patients had a worsening of the eGFR >10 and in 11 (8%) patients SV was stopped to due intolerability.

Conclusion

The clinical use of SV in our centre has a high rate of tolerability with significant improvement in NYHA class (31%) and excellent 6-month and 1-year outcomes. However, in a large proportion of patients, the target dose was not achieved (45%), mainly due to reported dizziness and postural blood pressure drop.

Conflict of interest statement

None.

View this table:
  • View inline
  • View popup
Table 1.

Baseline characteristics

View this table:
  • View inline
  • View popup
Table 2.

Outcome measures

  • © Royal College of Physicians 2019. All rights reserved.
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Sacubitril/valsartan in chronic heart failure – early clinical experience from a tertiary centre
Danish Ali, Jacqui Hyland, Fiona Riley, Stephanie Kirkland, Sarah Al Bared, Parekh Rajen, Lisa Hinitt, Catherine Watson, Hayley Nicholson, Umar Fraz, Prithwish Banerjee
Clinical Medicine Mar 2019, 19 (Suppl 2) 21-22; DOI: 10.7861/clinmedicine.19-2-s21

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Sacubitril/valsartan in chronic heart failure – early clinical experience from a tertiary centre
Danish Ali, Jacqui Hyland, Fiona Riley, Stephanie Kirkland, Sarah Al Bared, Parekh Rajen, Lisa Hinitt, Catherine Watson, Hayley Nicholson, Umar Fraz, Prithwish Banerjee
Clinical Medicine Mar 2019, 19 (Suppl 2) 21-22; DOI: 10.7861/clinmedicine.19-2-s21
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Aims
    • Methods
    • Results
    • Conclusion
    • Conflict of interest statement
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • An experimental series investigating the factors that influence the effect of hyperinsulinaemic euglycaemia on myocardial blood flow reserve
  • Specialist emergency care and COPD outcomes
  • A multi cross-site survey on Trichomonas vaginalis diagnosis in the Barts Health NHS Trust, London
Show more Clinical

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians